Napabucasin (BBI-608), a first-in-class stemness inhibitor, is being studied in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.
In results from the phase Ib/II study presented at the 19th World Congress on Gastrointestinal (GI) Cancer, this combination was shown to be safe and demonstrated encouraging signs of efficacy. Read more . . .